12/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center

项目摘要 12/14 APOL 1长期肾移植结局网络（APOLLO）临床中心 我们根据RFA-DK-22-506提交本申请。UCSF是APOLLO的现任成员 财团该联盟成立于2017年，与器官协会无缝合作， 采购组织（AOPO）招募参与者参加迄今为止最大的肾脏观察性研究 移植受体和供体评估APOL 1基因突变作为移植物丢失的风险因素。我们的临床 中心一直是西海岸的领导者，与我们在加州洛杉矶大学的研究中心合作 洛杉矶、加州戴维斯大学（UC Davis）、加州太平洋医疗中心（CPMC）、斯坦福大学 南加州大学。在第1阶段或APOLLO中，我们成功招募了 在这些中心的223名参与者中，有221/223的DNA标本在手。我们的网站已经监督了 从我们自己的研究中心和我们的参与者的电子病历中仔细收集临床数据 准确完整地填写APOLLO联盟数据表。在第二阶段，我们将 继续获得所有参与者的关键后续数据，并确保完成数据提取， 电子病历继续在我们参与的研究中心，以提供患者级别的详细信息， 由器官共享联合网络（UNOS）和移植科学登记处维护的数据库 收件人（SRTR）。我们将确保在所有参与者中测量尿白蛋白与肌酐的比值， 研究中心，在APOLLO I期研究中移植后至少2年的纵向随访时间点。我们将 收集额外的生物标本，用于生物储存库以及未染色的活检载玻片， 在第一阶段所做的事情。我们将与科学数据和协调中心合作， 将基因型结果返回给所有需要此信息的研究参与者。我们还将继续招聘 活体捐赠者阿波罗联盟的继续将导致我们的重要进展， 了解APOL 1高风险状态及其对移植物功能的影响以及APOL 1的生物学 基因效应

PROJECT SUMMARY 12/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center We submit this application in response to RFA-DK-22-506. UCSF is a current member of the APOLLO Consortium. This Consortium was established in 2017 to work seamlessly with the Association of Organ Procurement Organizations (AOPO) to enroll participants in the largest observational study to date of kidney transplant recipients and donors to evaluate APOL1 gene mutations as a risk factor for graft loss. Our Clinical Center has been a leader on the West Coast, collaborating with our sites at University of California Los Angeles, University of California Davis (UC Davis), California Pacific Medical Center (CPMC), Stanford University, and University of Southern California. In Phase 1 or APOLLO, we have successfully enrolled a total of 223 participants across these centers, with DNA specimens in hand for 221/223. Our site has overseen the careful collection of clinical data from the electronic medical record at our own site and those of our engaged centers to complete the APOLLO Consortium Data forms accurately and completely. In Phase 2, we will continue to obtain critical follow-up data on all participants and ensure completion of data abstraction from electronic medical record continues at our engaged sites, to provide patient-level detail not available in databases maintained by United Network for Organ Sharing (UNOS) and the Scientific Registry of Transplant Recipients (SRTR). We will ensure a urine albumin-to-creatinine ratio is measured in all participants, at all sites, at a longitudinal follow-up time point at least two years after transplantation in APOLLO Phase 1. We will collect additional biospecimens for contribution to the biorespository as well as unstained biopsy slides as we have been doing through Phase 1. We will work with the Scientific Data and Coordinating Center to ensure return of genotype results to all study participants who desire this information. We will also continue to recruit living donors at our site. Continuation of the APOLLO Consortium will lead to important advances in our understanding of APOL1 high-risk status and its influence on graft function as well as the biology of APOL1 gene effects.